Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Veracyte (VCYT) Operating Expenses (2016 - 2026)

Veracyte's Operating Expenses history spans 14 years, with the latest figure at $64.8 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 13.14% to $64.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $304.8 million, a 8.07% increase, with the full-year FY2025 number at $304.8 million, up 8.07% from a year prior.
  • Operating Expenses hit $64.8 million in Q4 2025 for Veracyte, down from $68.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for VCYT hit a ceiling of $100.3 million in Q4 2023 and a floor of -$35.1 million in Q4 2022.
  • Historically, Operating Expenses has averaged $72.6 million across 5 years, with a median of $76.8 million in 2021.
  • Biggest five-year swings in Operating Expenses: crashed 144.1% in 2022 and later surged 385.43% in 2023.
  • Tracing VCYT's Operating Expenses over 5 years: stood at $79.7 million in 2021, then crashed by 144.1% to -$35.1 million in 2022, then surged by 385.43% to $100.3 million in 2023, then fell by 25.64% to $74.6 million in 2024, then dropped by 13.14% to $64.8 million in 2025.
  • Business Quant data shows Operating Expenses for VCYT at $64.8 million in Q4 2025, $68.3 million in Q3 2025, and $95.0 million in Q2 2025.